Japanese companies Teijin Limited (TYO: 3401) and JCR Pharmaceuticals (TYO 4552) have decided to terminate their co-development and Japan licensing agreement aimed at developing JTR-161, an allogeneic regenerative medical product containing dental pulp stem cells (DPCs) for the intended purpose of helping patients recover from acute cerebral infarctions (strokes).
Shares of JCR fell 5.5% to 1,288 yen by close of trading Thursday, following the announcement, but those of Teijin were barely changed.
Using DPC isolated from human teeth extraction bodies, JTR-161 was expected to effectively suppress inflammation through immune regulatory factors and stimulate organ regeneration through trophic factors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze